EP1054876A1 - Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh - Google Patents

Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh

Info

Publication number
EP1054876A1
EP1054876A1 EP98958896A EP98958896A EP1054876A1 EP 1054876 A1 EP1054876 A1 EP 1054876A1 EP 98958896 A EP98958896 A EP 98958896A EP 98958896 A EP98958896 A EP 98958896A EP 1054876 A1 EP1054876 A1 EP 1054876A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
thiadiazole
alkyl
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98958896A
Other languages
German (de)
English (en)
Inventor
Paolo Pevarello
Raffaella Amici
Manuela Villa
Salvatore Toma
Mario Varasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of EP1054876A1 publication Critical patent/EP1054876A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2

Definitions

  • the present invention relates to novel 1,3,4-thiadiazoles compounds, to a process for their preparation, to pharmaceutical compositions containing them and to their use in therapy.
  • the compounds of the invention act as inhibitors of Kynurenine-3-hydroxylase (KYN- OH), an enzyme which forms part of the metabolic pathway of kynurenine. It is well known that through the kynurenine pathway, tryptophan metabolism gives rise to the formation of 3-hydroxy-kynurenine(3-OH-KYN) and quinolinic acid (QUIN), on the one side, and kynurenic acid (KYNA), on the other side, as shown in Figure 1. (The legend to Figure 1 is to be found on the last page of the experimental part of the specification).
  • KYNA is endowed with neuroprotective properties (J. Neurosci. 1990,10,2965-2973), whereas QUIN is a potent neurotoxin which has been implicated in the pathogenesis of a variety of neurological disorders (Life Sci. 1984,35,19-32; Nature, 1986,321 ,168-171 ; Science, 1983,219,316-318).
  • the present invention provides the use of a 1 ,3,4-thiadiazole compound of formula (I)
  • N(R 4 R 5 ) group in which each of R 4 and R 5 is independently hydrogen, C
  • X is oxygen or sulfur;
  • R is CC1 3 , CF 3 , a N(R 7 R g ) group, in which each of R 7 and R 8 is independently hydrogen or C C 6 alkyl or R 7 and R 8 taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring or R is a phenyl or naphthyl ring, wherein such heterocyclic, phenyl or naphthyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C,-C 6 alkyl, hydroxy, C C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a S0 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is as defined above, and a N(R 4 R 5 ) group, in which each of R 4 and R
  • Ri is hydrogen, CH 2 OPO 3 H , a -(CH 2 ) n -N(R 9 R 10 ) group in which n is an integer of 1 to 4 and each of R 9 and R 10 is independently hydrogen, C C 6 alkyl or phenyl, or R 9 and R 10 , taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring; or R, is a group of formula:
  • X, Y, p and R are independently as defined above; or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use as kynurenine-3-hydroxylase enzyme inhibitor.
  • a further object of the present invention is also to provide a 1,3,4-thiadiazole compound of formula (I),
  • Q represents a C 6 -C 14 aromatic ring system or a saturated or unsaturated heteromonocychc or heterobicyclic ring containing one or two heteroatoms chosen from oxygen, sulfur and nitrogen, wherein said aromatic or heterocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C r C 6 alkyl, hydroxy, C,-C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a S0 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is independently hydrogen, C r C 6 alkyl or phenyl, and a N(R 4 R 5 ) group, in which each of R 4 and R 5 is independently hydrogen, C C 6 alkyl or SO 2 R 6 , in which R 6 is C r C 6 alkyl or phenyl, or R 4 and R 5
  • X is oxygen or sulfur
  • R is CC1 3 , CF 3 , a N(R 7 R 8 ) group, in which each of R 7 and R 8 is independently hydrogen or C,-C 6 alkyl or R 7 and R 8 taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring or R is a phenyl or naphthyl ring, wherein such heterocyclic, phenyl or naphthyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C r C 6 alkyl, hydroxy, C,-C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a S0 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is as defined above, and a N(R 4 R 5 ) group, in which each of R
  • R is hydrogen, CH 2 OPO 3 H 2 , a -(CH 2 ) n -N(R 9 R ⁇ 0 ) group in which n is an integer of 1 to 4 and each of R 9 and R 10 is independently hydrogen, C r C 6 alkyl or phenyl, or R 9 and R 10 , taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring; or R, is a group of formula:
  • X, Y, p and R are independently as defined above; or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance, in particular as kynurenine-3- hydroxylase enzyme inhibitor.
  • the present invention also provides a method of treating a mammal, including human, in need of a kynurenine-3-hydroxylase inhibitor, such method comprising administering thereto a therapeutically effective amount of a 1 ,3,4-thiadiazole compound of formula (I)
  • Q represents a C 6 -C 14 aromatic ring system or a saturated or unsaturated heteromonocyclic or heterobicyclic ring containing one or two heteroatoms chosen from oxygen, sulfur and nitrogen, wherein said aromatic or heterocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C,-C 6 alkyl, hydroxy, C r C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a S0 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is independently hydrogen, C,-C 6 alkyl or phenyl, and a N(R R 5 ) group, in which each of R and R 5 is independently hydrogen,
  • R 6 is C r C 6 alkyl or phenyl, or R 4 and R 5 , taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring;
  • X is oxygen or sulfur;
  • Y is oxygen, sulfur or NH;
  • p is 0 or 1 ;
  • R is CC1 3 , CF 3 , a N(R 7 R 8 ) group, in which each of R 7 and R 8 is independently hydrogen or C r C 6 alkyl or R 7 and R 8 taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring or R is a phenyl or naphthyl ring, wherein such heterocyclic, phenyl or naphthyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C,-C 6 alkyl, hydroxy, C,-C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a S0 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is as defined above, and a N(R 4 R 5 ) group, in which each of R
  • X, Y, p and R are independently as defined above; or a pharmaceutically acceptable salt thereof.
  • Object of the present invention is also to provide a new 1 ,3,4-thiadiazole compound of formula (I)
  • Q represents a C 6 -C 14 aromatic ring system or a saturated or unsaturated heteromonocychc or heterobicyclic ring containing one or two heteroatoms chosen from oxygen, sulfur and nitrogen, wherein said aromatic or heterocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C r C 6 alkyl, hydroxy, C,-C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a SO 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is independently hydrogen, C r C 6 alkyl or phenyl, and a N(R 4 R 5 ) group, in which each of R 4 and R 5 is independently hydrogen, C r C 6 alkyl or SO 2 R 6 , in which R 6 is C,-C 6 alkyl or phenyl, or R 4 and R
  • R is CC1 3 , CF 3 , a N(R 7 R g ) group, in which each of R 7 and R 8 is independently hydrogen or C,-C 6 alkyl or R 7 and R 8 taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring or R is a phenyl or naphthyl ring, wherein such heterocyclic, phenyl or naphthyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C r C 6 alkyl, hydroxy, C r C 6 alkoxy, nitro, formylamino, C 2 -C 8 alkanoylamino, C 2 -C 8 alkanoyloxy, a SO 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is as defined above, and a N(R 4 R 5 ) group, in which each of R
  • the present invention also include within its scope all possible isomers. stereoisomers and optical isomers and their mixtures, and both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of the invention.
  • alkyl, alkanoyloxy, alkoxy and alkanoylamino groups may be branched or straight chain groups.
  • -C 6 alkyl groups include C,-C 4 alkyl groups such as methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.
  • C r C 6 alkoxy groups include C,-C 4 alkoxy groups such as methoxy or ethoxy.
  • C 2 -C 8 alkanoylamino include C 2 -C 4 alkanoyl groups such as acetylamino or propionylamino.
  • Representative examples of C 2 -C 8 alkanoyloxy include C 2 -C 4 alkanoyl groups such as acetoxy or propionyloxy.
  • Q is a C 6 -C 14 aromatic ring system, it is preferably phenyl or naphthyl; when Q is a saturated or unsaturated heteromonocychc or heterobicyclic ring as defined above, it is preferably chosen from pyridine, imidazole, pyrrolidine, morpholine, piperidine, piperazine, 3-azabicyclo[3.2.2]nonane, cycloheptylamine and 1 ,2,5,6-tetrahydropyridine and it is linked to the [l,3,4]thiadiazole(alkyl) moiety through either a carbon or a nitrogen atom, as known in the art.
  • R 4 and R 5 or R 7 and R 8 or Re, and R i0 taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring
  • said ring is preferably chosen from pyridine, imidazole, pyrrolidine, morpholine, piperidine, piperazine, cycloheptylamine and 1,2,5,6-tetrahydropyridine.
  • a halogen atom is fluorine, bromine, chlorine or iodine; in particular chlorine or fluorine.
  • Pharmaceutically acceptable salts of the compounds of the invention include base addition salts with inorganic bases, e.g. sodium, potassium, calcium and aluminium hydroxydes or with organic bases, e.g. lysine, triethylamine, triethanolamine.
  • dibenzylamine methylbenzylamine, di-(2-ethyl-hexyl)-amine, piperidine, N-ethylpiperidine, N,N- diethylaminoethylamine, N-ethyl-morpholine, ⁇ -phenethyiamine, N-benzyl- ⁇ - phenethylamine, N-benzyl-N,N-dimethylamine and the other acceptable organic amines, as well as the salts with inorganic, e.g. hydrochloride, hydrobromic and sulphuric acids and with organic acids, e.g. citric, tartaric, maleic, malic, fumaric, methanesulphonic, ethanesulphonic and isethionic acids.
  • inorganic e.g. hydrochloride, hydrobromic and sulphuric acids and with organic acids, e.g. citric, tartaric, maleic, malic, fumaric, methanes
  • Preferred compounds of formula (I) are those wherein; m is zero or 1 ; X, Y and p are as defined above; Q represents a phenyl, naphthyl, pyridyl, imidazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, 3-azabicyclo[3.2.2]nonyl, cycloheptylamino or 1 ,2,5,6- tetrahydropyridyl ring, wherein said ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, CF 3 , C,-C alkyl, C,-C 4 alkoxy, nitro, a SO 2 N(R 2 R 3 ) group, in which each of R 2 and R 3 is independently hydrogen or C,-C 4 alkyl, and a N(R 4 R 5 ) group in which each of R 4 and R 5 is independently hydrogen, C,-C alky
  • R is hydrogen, CH 2 OPO 3 H 2 , a -(CH 2 ) n -N(R 9 R, 0 ) group in which n is an integer of 2 to 4 and each of R 9 and R 10 is independently hydrogen, C,-C 4 alkyl or phenyl or R 9 and R 10 , taken together with the nitrogen atom to which they are linked, form a saturated or unsaturated C 5 -C 7 heterocyclic ring; or R, is a group of formula:
  • X, Y, R and p are as defined above; and the pharmaceutically acceptable salts thereof.
  • Examples of preferred compounds of formula (I) are the following: 2-[N-(2,2,2-trichloroethyloxycarbonyl)-amino]-5-phenyl-[l,3,4]thiadiazole;
  • the compounds of the present invention and the salts thereof can be obtained, for instance, by a process comprising: a) reacting a compound of formula (II)
  • Ri is hydrogen; or d) hydrogenolising a compound of formula (VI)
  • reaction between a compound of formula (II) and a compound of formula (III) can be carried out, for example, in the presence of a base such as triethylamine, potassium carbonate, in a suitable solvent such as dichloromethane, acetone, dioxane, acetonitrile, toluene, at a temperature ranging from about -20°C to reflux.
  • a base such as triethylamine, potassium carbonate
  • a suitable solvent such as dichloromethane, acetone, dioxane, acetonitrile, toluene
  • R is either hydrogen or a - CX-Y-(CH 2 ) p -R group.
  • the reaction between a compound of formula (I) as defined under process b) and a compound of formula (IV) can be carried out, for example, in a suitable solvent such as toluene or dichloromethane, at a temperature ranging from about -20°C to reflux.
  • a suitable solvent such as toluene or dichloromethane
  • the reaction between a compound of formula (V) and a compound of formula (IV) can be carried out, for example, in a suitable solvent such as toluene, dichloromethane, chloroform, diethyl ether, at a temperature ranging from about -20°C to reflux.
  • the hydrogenolysis of a compound of formula (VI) can be carried out.
  • the leaving group Z is a common leaving group, typically halogen or a mesyl or tosyl group.
  • the reaction between a compound of formula (I), wherein R, is hydrogen, and a compound of formula (VII) can be carried out, for example, in the presence of a base such as sodium hydride, potassium carbonate, potassium or sodium hydroxyde, in a suitable solvent such as N,N-dimethylformamide, tetrahydrofurane, dioxane, acetonitrile, toluene, at a temperature ranging from about -20°C to reflux.
  • a base such as sodium hydride, potassium carbonate, potassium or sodium hydroxyde
  • suitable solvent such as N,N-dimethylformamide, tetrahydrofurane, dioxane, acetonitrile, toluene
  • the optional conversion of a compound of formula (I) into another compound of formula (I) can be carried out according to known methods; processes b) and e) are examples of such conversions.
  • a nitro group may be converted into an amino group by treatment, for example, with stannous chloride in concentrated hydrochloric acid, using, if necessary, an organic cosolvent such as acetic acid, dioxane, tetrahydrofuran at a temperature varying between room temperature and about 100°C.
  • an organic cosolvent such as acetic acid, dioxane, tetrahydrofuran at a temperature varying between room temperature and about 100°C.
  • an amino group may be converted into a formylamino or a C 2 -C 8 alkanoylamino group, for example by reacting with formic acid or with the suitable C 2 -C 8 alkanoylanhydride without any solvent or in an organic solvent such as dioxane, N,N-dimethylformamide, tetrahydrofuran, usually in the presence of a base such as pyridine or triethylamine, at a temperature varying between 0°C and about 100°C.
  • a base such as pyridine or triethylamine
  • the intermediate compounds of formula (II), (III), (IV), (V) and (VII) are known compounds or can be obtained according to known methods.
  • a compound of formula (II), wherein m is zero and Q is a heteromonocychc or a heterobicyclic ring, linked to the [1.3,4]thiadiazole moiety through a nitrogen atom can be obtained, for example, by reacting a compound of formula (VIII)
  • a heteromonocychc or a heterobicyclic amine in the presence of a base, such as potassium carbonate, triethylamine, sodium hydride, in a suitable solvent, such as ethanol, DMSO, tetrahydrofuran at a temperature varying between about 0°C and about 100°C.
  • a base such as potassium carbonate, triethylamine, sodium hydride
  • a suitable solvent such as ethanol, DMSO, tetrahydrofuran at a temperature varying between about 0°C and about 100°C.
  • a compound of formula (II), wherein m is zero or 1 and Q is phenyl, pyridyl, naphthyl, or imidazolyl can be obtained by a process comprising: f) reacting a compound of formula (IX)
  • a compound of formula (I) as defined in process b) can be obtained by reacting a compound of formula (II) with trichloromethyl carbonate or trichloromethylchloroformate, in the presence of a base, such as triethylamine, in a suitable solvent, such as dichloromethane, toluene, at a temperature ranging from about -20°C to reflux.
  • a base such as triethylamine
  • a suitable solvent such as dichloromethane, toluene
  • a compound of formula (V) can be prepared by reacting a compound of formula (II) with trichloromethylcarbonate or trichloromethylchloroformate, in a suitable solvent, such as . dichloromethane, toluene, at a temperature ranging from about -20°C to reflux.
  • a suitable solvent such as . dichloromethane, toluene, at a temperature ranging from about -20°C to reflux.
  • a compound of formula (VI) can be prepared, for example, by reacting a compound of formula (XII)
  • a compound of formula (XII) can be prepared, for example, by reacting a compound of formula (XIII)
  • a compound of formula (XIII) can be obtained, for example, by reacting a compound of formula (I), wherein R, is hydrogen, with formaldehyde, in the presence of a base such as potassium or cesium carbonate, in a suitable solvent, such as tetrahydrofurane or water, at a temperature ranging from room temperature to reflux.
  • a base such as potassium or cesium carbonate
  • a suitable solvent such as tetrahydrofurane or water
  • the compounds of formula (VIII), (IX), (X) and (XI), are, in some cases, commercially available products, or may be prepared by methods well known in the art.
  • groups are present which may interfere with the hereabove illustrated reactions, they may be protected before the reactions take place and then deprotected at the end of the reactions, according to well known methods in organic chemistry.
  • the compounds of the invention are active as kynurenine-3-hydroxylase enzyme inhibitors and therefore are useful in the prevention and/or treatment of neuropathological processes, related to a deranged production of QUIN and/or 3-OH-KYN due to excessive activation of neurotransmission mediated by excitatory amino acid receptors and/or oxidative stress.
  • neuropathological processes are neurodegenerative pathologies including, e.g.
  • Alzheimer's chorea Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy, non- Alzheimer's dementias, including the dementia like syndrome caused by Acquired Immunodeficiency Syndrom (AIDS), multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal and head trauma, and epilepsy.
  • AIDS Acquired Immunodeficiency Syndrom
  • a human or animal in need of a kynurenine-3 -hydroxy lase enzyme inhibitor can thus be treated by a method which comprises the administration thereto of a therapeutically effective amount of a compound of the invention or a salt thereof.
  • the condition of the human or animal can thereby be improved.
  • the assay for kynurenine 3-hydroxylase is based on the enzymatic synthesis of tritiated water during the hydroxylation reaction. Radiolabeled water was quantified following selective adsorption of the isotopic substrate and its metabolite with activated charcoal. Rat liver mitochondrial extract was used as enzymatic preparation for this assay. The assay for kynurenine 3-hydroxylase activity was carried out at 37°C for a time of 30 min.
  • the reaction mixture of a total volume of 30 ⁇ l was constituted of 44 ⁇ g of suspended extract, 100 mM Tris /Cl " buffer pH 8.1, 10 mM EDTA, 100 mM KC1, 0.8 mM NADPH, 0.025 mM L-Kynurenine, 0.3 ⁇ Ci L-(3,5- 3 H)Kynurenine (10 Ci/mmol) and 3 ⁇ l of different concentration of inhibitor solutions. After the incubation, the reaction was terminated by the addition of 300 ⁇ l of 7.5 (W/v) activated charcoal, and centrifuged for 7 min..
  • the dosage level suitable for administration to a mammal, e.g.: to humans, depends on the age, weight, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration e.g. for the representative compound of the invention PNU 153833 may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily.
  • the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.
  • dosage forms e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.
  • the invention includes also pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).
  • a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyviny
  • a starch alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
  • the liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
  • the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa
  • reaction mixture was refluxed for about 6h, concentrated to a small volume (50 ml) and filtered; the residue was washed with ethanol, ice-cooled water (2X5 ml), suspended in IN NaOH (31 ml) while cooling and neutralized to pH 7 with IN HC1. The resulting solid was filtered, washed with water and dried in vacuo at 80°C to yield the title compound as a beige solid (5.0 g; 47%): m.p. 204-206°C
  • the following products can be prepared: l-phenyl-3-(5-pyridin-3-yl-[l,3,4]thiadiazol-2-yl)-urea; 2-[N-(2,2,2-trifluoroethyloxycarbonyl)-amino]-5-phenyl-[l,3,4]thiadiazole; l-phenyl-3-(5-phenyl-[l,3,4]thiadiazol-2-yl)-urea; and
  • Capsule each weighing 0.23 g and containing 50 mg of the active substance can be prepared as follows: Composition for 500 capsules: 2-[N-(2,2,2-trichloroethyloxycarbonyl)-amino]-5-phenyl-[ 1 ,3,4]thiadiazole 25 g Lactose 80 g
  • This formulation can be incapsulated in two hard gelatin capsules of two pieces, each with each capsule weighing 0.23 g.
  • a pharmaceutical injectable composition can be manifactured dissolving 50 g 2-[N-(2,2,2- trichloroethyloxycarbonyl)-amino]-5-phenyl-[l,3,4]thiadiazole in sterile propyleneglycol
  • KYN-OH Kynurenine-3-hydroxylase
  • KAT kynurenine amino transferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I) dans laquelle m représente 0 ou 1; Q représente un système de cycle aromatique C6-C14 ou un cycle hétéromonocyclique ou hétérobicyclique facultativement substitué, saturé ou insaturé, contenant un ou deux hétéroatomes choisis entre l'oxygène, le soufre et l'azote; X représente oxygène ou soufre; Y représente oxygène, soufre ou NH; p représente 0 ou 1; R représente CCl3, CF3, un groupe N(R7R8), dans lequel R7 et R8 représentent chacun indépendamment hydrogène ou alkyle C1-C6 ou R7 ainsi que R8 pris ensemble avec l'atome d'azote auquel ils sont liés forment un cycle hétérocyclique C5-C7 saturé ou insaturé, ou R représente un cycle phényle ou naphtyle facultativement substitué; R1 représente hydrogène, CH2OPO3H2, un groupe -(CH2)n-N(R9R10) dans lequel n représente un nombre entier compris entre 1 et 4 et R9 ainsi que R10 représentent chacun indépendamment hydrogène, phényle ou alkyle C1-C6, ou R9 ainsi que R10, pris ensemble avec l'atome d'azote auquel ils sont liés, forment un cycle hétérocyclique C5-C7 saturé ou insaturé; ou R1 représente un groupe de la formule (A) dans laquelle X, Y, p et R sont définis indépendamment tel que ci-dessus; ainsi que les sels acceptables sur le plan pharmaceutique desdits composés lesquels présentent une activité inhibant l'enzyme kynurénine-3-hydroxylase.
EP98958896A 1997-11-26 1998-10-27 Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh Withdrawn EP1054876A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9725055.9A GB9725055D0 (en) 1997-11-26 1997-11-26 1,3,4-thiadiazoles compounds
GB9725055 1997-11-26
PCT/EP1998/006995 WO1999028309A1 (fr) 1997-11-26 1998-10-27 Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh

Publications (1)

Publication Number Publication Date
EP1054876A1 true EP1054876A1 (fr) 2000-11-29

Family

ID=10822700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98958896A Withdrawn EP1054876A1 (fr) 1997-11-26 1998-10-27 Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh

Country Status (6)

Country Link
EP (1) EP1054876A1 (fr)
JP (1) JP2001524547A (fr)
AU (1) AU1487599A (fr)
CA (1) CA2310008A1 (fr)
GB (1) GB9725055D0 (fr)
WO (1) WO1999028309A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204750B1 (pl) * 2004-03-26 2010-02-26 Univ Przyrodniczy W Lublinie Pochodna 1,3,4-tiadiazolu , zastosowanie pochodnej 1,3,4-tiadiazolu w leczeniu chorób neurologicznych oraz sposób otrzymywania pochodnej 1,3,4-tiadiazolu
EP2054397B1 (fr) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Inhibiteurs à petites molécules de kynurénine-3-monooxygénase
EP2420494B1 (fr) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Utilisation de composes derives de thiadiazoles comme inhibiteurs de la kynurenine-3- monooxygenase
EP2558458B1 (fr) * 2010-04-16 2017-09-06 Bayer Intellectual Property GmbH Nouveaux composés hétérocycliques en tant qu'agents antiparasitaires
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
WO2022026823A1 (fr) * 2020-07-31 2022-02-03 Chan Zuckerberg Biohub, Inc. Inhibiteurs sélectifs de cdk19 et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5519055A (en) * 1993-08-06 1996-05-21 University Of Maryland At Baltimore Substituted kynurenines and process for their preparation
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9618349D0 (en) * 1996-09-03 1996-10-16 Pharmacia Spa N-substituted 2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibitory activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9928309A1 *

Also Published As

Publication number Publication date
GB9725055D0 (en) 1998-01-28
JP2001524547A (ja) 2001-12-04
AU1487599A (en) 1999-06-16
WO1999028309A1 (fr) 1999-06-10
CA2310008A1 (fr) 1999-06-10

Similar Documents

Publication Publication Date Title
JP2588265B2 (ja) 複素環式化合物
JP5734628B2 (ja) インドール化合物及びその医薬用途
AU2009264273B2 (en) Squaric acid derivatives as inhibitors of the nicotinamide
AU2004226281B2 (en) Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses
US9765054B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
WO2013020371A1 (fr) Inhibiteur de pim kinase, son procédé de préparation et son utilisation dans la préparation de médicament
AU2006234413A1 (en) NPY antagonists, preparation and use
BRPI9603626B1 (pt) derivados de 2,3-dioxo-1,2,3,4-tetraidro-quinoxalinila e composição farmacêutica contendo os mesmos
RU2109735C1 (ru) Оксопропаннитрильные производные конденсированного пиразола или их фармацевтически приемлемые соли, проявляющие иммуностимулирующую активность, и фармацевтическая композиция
US6750225B2 (en) 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
EP1054876A1 (fr) Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh
US7910739B2 (en) Acetylcholinesterase dual inhibitors
CN105820163A (zh) 取代的1,3-杂唑类化合物、其制备方法、包含其的药物组合物及用途
EP1036069A1 (fr) Composes benzenesulfamides
JPH09508404A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
JP2001512107A (ja) 融合ヘテロ環式化合物及びそのキヌレニン−３−ヒドロキシラーゼ阻害剤としての使用
WO1999016753A2 (fr) Composes 3-oxo-propanenitrile tricycliques
EP1025105A1 (fr) Composes benzothiopyraniques condenses
EP1034176A1 (fr) Composes thiophene-sulfamides
WO1999006374A1 (fr) Composes heterocycliques condenses
US20160096832A1 (en) Kinase inhibitors
KR20060099287A (ko) 펩타이드 디포밀라제 활성 억제 화합물, 이의 제조방법 및이를 함유하는 약학 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000530;LT PAYMENT 20000530;LV PAYMENT 20000530;MK PAYMENT 20000530;RO PAYMENT 20000530;SI PAYMENT 20000530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010223